Spero Therapeutics (NASDAQ:SPRO) had its price target increased by HC Wainwright from $28.00 to $35.00 in a research report released on Tuesday, AnalystRatings.com reports. They currently have a buy rating on the stock.
A number of other brokerages have also issued reports on SPRO. Zacks Investment Research lowered Spero Therapeutics from a buy rating to a hold rating in a research note on Thursday, September 12th. ValuEngine raised Spero Therapeutics from a sell rating to a hold rating in a research note on Friday, November 1st. TheStreet downgraded Spero Therapeutics from a c- rating to a d+ rating in a research note on Monday, July 29th. Oppenheimer dropped their price target on Spero Therapeutics from $30.00 to $20.00 in a research note on Wednesday, October 2nd. Finally, Janney Montgomery Scott initiated coverage on Spero Therapeutics in a research note on Monday, September 9th. They issued a buy rating on the stock. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Spero Therapeutics has a consensus rating of Buy and an average price target of $23.50.
Shares of SPRO traded down $0.04 during trading hours on Tuesday, reaching $10.53. 23,700 shares of the company traded hands, compared to its average volume of 60,168. The company’s fifty day moving average price is $10.79 and its two-hundred day moving average price is $10.98. Spero Therapeutics has a 12 month low of $5.52 and a 12 month high of $14.48. The company has a market capitalization of $195.89 million, a price-to-earnings ratio of -4.05 and a beta of 2.09. The company has a quick ratio of 13.66, a current ratio of 6.90 and a debt-to-equity ratio of 0.04.
Spero Therapeutics (NASDAQ:SPRO) last released its quarterly earnings results on Monday, November 4th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.10). Spero Therapeutics had a negative net margin of 287.11% and a negative return on equity of 43.10%. The company had revenue of $4.64 million during the quarter, compared to analyst estimates of $2.03 million. On average, analysts expect that Spero Therapeutics will post -3.06 EPS for the current year.
Several large investors have recently added to or reduced their stakes in the stock. Marshall Wace LLP bought a new stake in Spero Therapeutics during the first quarter worth about $39,000. Wells Fargo & Company MN boosted its holdings in Spero Therapeutics by 187.9% in the 2nd quarter. Wells Fargo & Company MN now owns 13,660 shares of the company’s stock worth $157,000 after buying an additional 8,915 shares during the period. JPMorgan Chase & Co. boosted its holdings in Spero Therapeutics by 9.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 164,389 shares of the company’s stock worth $1,826,000 after buying an additional 13,814 shares during the period. Acadian Asset Management LLC bought a new position in Spero Therapeutics in the 2nd quarter worth approximately $25,000. Finally, AWM Investment Company Inc. boosted its holdings in Spero Therapeutics by 6.4% in the 2nd quarter. AWM Investment Company Inc. now owns 598,315 shares of the company’s stock worth $6,887,000 after buying an additional 36,019 shares during the period. 50.98% of the stock is currently owned by institutional investors and hedge funds.
About Spero Therapeutics
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections.
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.